Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-01-03 08:30 |
Cantargia advances nadunolimab against pancreatic cancer in the PanCAN Precisio…
|
English | 207.9 KB | ||
| 2021-12-29 14:15 |
Cantargia rapporterar uppdaterade lovande överlevnadsdata från CANFOUR-studien …
|
Swedish | 204.5 KB | ||
| 2021-12-29 14:15 |
Cantargia reports updated encouraging survival data from CANFOUR trial with nad…
|
English | 205.6 KB | ||
| 2021-12-22 13:08 | English | 36.0 KB | |||
| 2021-12-13 13:00 |
Cantargia reports positive results for CAN10 antibody in preclinical systemic s…
|
English | 195.4 KB | ||
| 2021-12-13 13:00 |
Cantargia rapporterar positiva resultat för antikroppen CAN10 i en preklinisk m…
|
Swedish | 193.7 KB | ||
| 2021-12-09 13:42 | English | 36.0 KB | |||
| 2021-12-03 11:36 | English | 36.1 KB | |||
| 2021-12-01 16:00 |
Cantargia reports opposition against recently granted European patent
|
English | 192.3 KB | ||
| 2021-12-01 16:00 |
Cantargia rapporterar om opposition mot nyligen godkänt europeiskt patent
|
Swedish | 194.6 KB | ||
| 2021-11-11 08:30 | Swedish | 805.9 KB | |||
| 2021-11-11 08:30 | English | 881.0 KB | |||
| 2021-11-08 15:45 |
Cantargia rapporterar framsteg i produktionsutvecklingen och uppdaterar kring f…
|
Swedish | 201.8 KB | ||
| 2021-11-08 15:45 |
Cantargia reports progress in manufacturing process development and provides up…
|
English | 204.4 KB | ||
| 2021-10-29 14:30 |
Valberedning utsedd inför årsstämman 2022
|
Swedish | 143.5 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
